William Blair on Janux Therapeutics (JANX): 'Exceeding Investor Expectations and Raising the Bar in mCRPC'
William Blair analyst Matt Phipps reiterated an Outperform rating on Janux Therapeutics (NASDAQ: JANX).The analyst comments "On Monday, December 2 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
